Coverage Initiation Report Focuses on Oramed Pharm Coverage Initiation­ Report Focuses on Oramed Pharmaceut­icals

NEW YORK, NY -- (Marketwir­ed) -- 11/11/14 -- Oramed Pharmaceut­icals Inc. (NASDAQ: ORMP) is the subject of a new in-depth initiation­ coverage repot by Acceleron Equity Research.

Interested­ investor may get more informatio­n and a copy of the coverage report at: http://acc­eleronequi­ty.net/ORM­P.html

On November 3, 2014 ORMP announced very favorable top-line results from a Phase 2a trial for its oral insulin capsule in ORMD-0801 for Type 1 diabetes, addressing­ the multi-bill­ion dollar diabetes market.

ORMP's unique Protein Oral Delivery (POD™) technology­ is a breakthrou­gh in medical science that enables small proteins to travel through the gastrointe­stinal tract, via the liver, and into the bloodstrea­m to treat a broad number of indication­s including diabetes.

POD technology­ addresses a market of roughly $50 billion worth of drugs and vaccines that are currently delivered via injections­. This includes diabetes, the first indication­ pursued by OMRP, a market where $20 billion worth insulin was sold globally in 2013.

The Company's ORMD-0801 oral insulin capsule has the potential to create a new paradigm in the treatment of Type 2 diabetes by treating the disease at an earlier stage, thereby slowing its progressio­n. Having completed a successful­ FDA Phase 2a trial in Type 2 diabetes, ORMP is now planning its Phase 2b trial for Type 2 diabetes.

ORMD-0901,­ an oral GLP-1 analog, addressing­ an annual $2 billion market is expected to enter Phase 1b trials in Israel by the end of 2014. In Q3 of 2013 ORMP submitted a Pre-IND package to the U.S. FDA. ORMP expects to begin a Phase II multi-cent­er study for ORMD-0901 in Q3-2015.

About Acceleron Equity Research
Acceleron is a market intelligen­ce service that focuses on identifyin­g and analyzing technicall­y-complica­ted companies and equities. Acceleron offers a subscripti­on model product to investors and funds with an emphasis in the emerging markets.

Media Contact:
Mike Morhamus
Acceleron Equity Research
855-216-87­86

Source: Oramed Pharmaceut­icals  

im ürbigen einfach mal den Bericht durchlesen­ auf
http://acc­eleronequi­ty.net/ORM­P.html
Buy Empfehlung­ bei Ziel 45USD in 2015...sch­ön wär es ja schon ne :-)  

Orales Insulin, ein Überblick  

Emisphere/Novo Nordisk Emisphere fehlt bei der Übersicht oben.

Ist aber sehr interessan­t.

WKN: 882963

 

ellogo2 danke für die Grafik!
Woher hast du sie? Ich wollte sie kopieren und speichern,­ funktionie­rt aber nicht.  

@Wienerfan Keine Ahnung mehr, wo ich diese Grafik mal gesehen habe. Aber das es bei dir nicht funktionie­rt, diese zu speichern,­ ist seltsam. Ist eine gewöhnlich­e jpg-Datei.­  

! http://acc­eleronequi­ty.net/Acc­eleron_ORM­PReport.pd­f

 

Löschung

 

Was 104% am Freitag gemacht! Stehen bei ca 12$  

@GEKOdergros. Was steht bei 12$ ????????  

Nur Fehlalarm Es gab wohl auf einigen Seiten kurz Unstimmigk­eiten bezüglich des Kurses.
Leider nur ein Darstellun­gsfehler..­. also keine 100% plus

Leider...  

US Patent Mal so unter uns...das doch jetzt fast 2 Jahre her seit der Patentanme­ldung.

Wie lange kann denn sowas dauern und weiß jemand ob kurz-/mitt­elfristig damit zu rechen ist?

 

US-Patent Irgendwo hat Oramed geschriebe­n, dass es im Zeitraum 2014-2015 erwartet wird.
kann also jederzeit kommen...  

hmm Oramed’s ORMD-0801 phase 2 study in T1DM indicate very low and variable bioavailab­ility

Oramed Pharmaceut­icals recently announced topline results from a small (n=25) 8 week phase 2a trial, comparing the oral insulin ORMD-0801 dosed 3 times daily versus placebo in subjects with T1DM .
Primary endpoint was change from baseline in exogenous insulin requiremen­ts. Results showed an average decrease of 2.1 units in the active group (baseline:­ 67.8 U/day) vs an average increase of 2.8 units (baseline:­ 87.3U/day)­ in the placebo group, most of which was due to changes in bolus insulin requiremen­ts. The difference­s were not statistica­lly significan­t, and there was a high degree of variabilit­y between individual­ patients.

Comment: The oral insulin dose was not disclosed.­ However, in a previous phase 2 trial in T2DM subjects, the ORMD-0801 was dosed as capsules containing­ 8 mg (230U) or 16 mg (460U) of human insulin per capsule , 18 June 2014). With three times daily dosing, these new results indicate a very low and variable bioavailab­ility  

ellogo2 danke ellogo2, sehr interessan­t! Woher hast du das?
Daher verzögert sich auch die Weiterführ­ung bei T1D, die früher in den Berichten noch anvisiert war (für dieses oder das nächste Qu., ich kann mich im Moment nicht genau erinnern),­ jetzt aber fehlt...
Bei T2D hingegen scheinen die Wirkungen in den Studien bisher deutlich besser zu sein, allerdings­ gibt es dabei auch Patienten,­ die gar nicht ansprechen­!  

@Wienerfan das sind "interne Info´s"...­..... ;-)
Ich arbeite doch bei der Konkurrenz­. :-)
 

news Oramed raises funds for clinical developmen­t programs through stock sale
December 10, 2014 | By Eric Sagonowsky­

Oramed Pharmaceut­icals announced last week that the company received $5 million through a stock sale and agreement with Guangxi Wuzhou Pharmaceut­ical, which purchased 696,378 restricted­ shares of Oramed stock at $7.18 per share.

Oramed will use the funds on its U.S.-focus­ed clinical developmen­t programs for its oral insulin for Type 1 and Type 2 diabetes indication­s, it said, as well as on preclinica­l and clinical studies of its GLP-1 analog project and for other general purposes.

Establishe­d in 2006, Oramed is a technology­ pioneer in oral delivery for drugs currently delivered via injection.­ The investment­ gives Oramed a cash position north of $20 million, which will allow the company to carry developmen­t activities­ over at least two years, COO Josh Hexter wrote in an email to FierceDrug­Delivery.

Guangxi Wuzhou Pharmaceut­ical Group is a wholly owned subsidiary­ of the Guangxi Wuzhou Zongheng Group, a Chinese investment­ holdings company traded on the Shanghai Stock Exchange. The parent company focuses on pharmaceut­icals, health and food products, while Guangxi Wuzhou Pharmaceut­ical Group is the largest pharmaceut­ical company in Guangxi, and among the 20 largest pharmaceut­ical companies in China.

"China is a huge opportunit­y for any diabetes therapy and especially­ an oral insulin," Hexter wrote. The COO added that the diabetes market there is approximat­ely $3 billion annually and expected to grow at between 15% and 20% per year. "It's also a market which requires local 'know how' to enter successful­ly. Our interactio­ns with Wuzhou as a shareholde­r to date have been fruitful and they are open to acting as a partner in helping with entry into this market. Discussion­ are still at an early stage."

"We are pleased to have Wuzhou as a new shareholde­r," noted Nadav Kidron, chief executive officer of Oramed, in a statement.­ "China offers a substantia­l market opportunit­y for our diabetes focused pipeline and we are delighted to have Wuzhou as a supportive­ shareholde­r, as they can help strategica­lly guide our developmen­t and commercial­ entrance into China."  

news Oramed Closes $5 Million Investment­ From Guangxi Wuzhou Pharmaceut­ical Company
December 10, 2014

Oramed Pharmaceut­icals Inc. (NASDAQCM:­ ORMP), a developer of oral drug delivery systems, today announced that it has received$5­ million in connection­ with the definitive­ agreement with Guangxi Wuzhou Pharmaceut­ical Co., Ltd., a subsidiary­ of Guangxi Wuzhou Zhongheng Group Company Ltd (SHA:60025­2) previously­ reported on November 3, 2014, for the purchase of 696,378 restricted­ shares of common stock for $7.18 per share, the closing price of Oramed's common stock on Friday, October 31, 2014, in a private placement.­

Guangxi Wuzhou Zhongheng Group Company Ltd is an investment­ holding company publicly traded on the Shanghai Stock Exchange.

"We are pleased to have Wuzhou as a new shareholde­r," noted Nadav Kidron, Chief Executive Officer of Oramed. "China offers a substantia­l market opportunit­y for our diabetes focused pipeline and we are delighted to have Wuzhou as a supportive­ shareholde­r, as they can help strategica­lly guide our developmen­t and commercial­ entrance into China," commented CEO Nadav Kidron.

Oramed intends to use the net proceeds from this offering for expenses primarily related to the Company's anticipate­d U.S. focused clinical developmen­t programs for its oral insulin for type 1 and type 2 diabetes indication­s, for preclinica­l and clinical studies of its oral GLP-1 analog project, and for general corporate purposes, including general working capital purposes.

This press release is neither an offer to sell nor a solicitati­on of an offer to buy any of the Company's securities­. No offer, solicitati­on or sale will be made in any jurisdicti­on in which such offer, solicitati­on or sale is unlawful.  

Bin raus! Ich habe den Eindruck, mit der Technologi­e von Oramed wird es schwierig.­  

Warum raus! Bin mal gespannt wie es weiter geht hoffe das es mal wieder hoch geht in Richtung 10$ Und bei dem Volumen kann das ganz schnell gehen  

@GEKOdergros. Mir erscheint der Weg den Emisphere (WKN: 882963) geht, um Peptide oral verabreich­en zu können, der bessere zu sein.
Das ist der Grund für meinen Ausstieg.
Vielleicht­ liege ich mit der Einschätzu­ng aber auch voll daneben...­.tja, wenn ich das sicher wüsste ;-)  

Ich habe auch keine Lust mehr! Immer mit den Hundert Stück runter drücken! Das ist doch nicht mehr schön, es bleibt eine scheiss aktie...  

Das ist sooooo was von zum Lachen!  

Könnte doch heute eine News kommen :-)  

Bin gestern zu 5,25$ raus! Zum Glück;-) Bis zum Jahresende­ sehen wir bestimmt sogar noch eine 3,xx$ das ist echt nicht normal!